Table 4.
Serious AEs, n (%) | Dacarbazine (n=287) | Vemurafenib (n=336) |
---|---|---|
≥1 serious AE | 52 (18) | 165 (49) |
Squamous cell carcinoma of the skin | 2 (<1) | 66 (20) |
Keratoacanthoma | 3 (1) | 36 (11) |
Basal cell carcinoma | 2 (<1) | 10 (3) |
Malignant melanoma | 0 | 7 (2) |
AEs, adverse events.